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Abstract
Background. In all cases of suspected sexually transmitted infections (STIs), it has been routine practice to screen
for syphilis with a blood sample. The incidence of syphilis seems to be lower than that of commonly screened
STIs. Objective. The objective of our study was to determine whether it is cost-effective to screen for syphilis
with serological testing in cases of suspected gonorrhea and chlamydia infections. Hypothesis. Our hypothesis
is that it is not cost-effective to screen for syphilis in cases of presumed gonorrhea and chlamydia infections.
Methods. Our study is a New York Medical College institutional review board–approved retrospective study.
During the period January 2004 to August 12, 2006, the laboratory work of all patients tested for gonorrhea
and chlamydia in our emergency department was reviewed. The charts were reviewed for the following tests:
gonorrhea DNA probe, chlamydia DNA probe, and syphilis IgG (immunoglobulin G)/RPR (rapid plasma reagin).
The results of these tests were obtained and analyzed. Results. The total number of patients screened for
gonorrhea and chlamydia during this period was 196. Seventy-eight patients tested positive for gonorrhea and
chlamydia. All these 78 patients, tested negative for syphilis. The overall prevalence of positivity for STIs was
39.8% (78/196). The prevalence of chlamydia alone was 85.9% (67/78) and gonorrhea alone was 7.69% (6/78).
The prevalence of combined both chlamydia and gonorrhea was 6.4% (5/78). Statistics. We used online SILICO
2 × 4 Fisher exact test. By comparing positive and negative results of serology RPR, GC, and chlamydia trap, the
resultant 2-tailed P value is <.0001, which is statistically significant. Conclusions. Per our study, the yield of syphilis
testing was negligible. It may not be cost-effective to screen for syphilis in cases of STIs such as gonorrhea and
chlamydia.
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Introduction

Materials and Methods

Our study is a New York Medical College institutional
review board–approved retrospective study. In all the
cases of suspected sexually transmitted infection (STI),
it is mandated by New York State to test for syphilis in
addition to testing for gonorrhea and chlamydia. In fact,
it is customary practice to draw a blood sample for syphilis for all sexually active adolescents who come for routine annual physical examination.1 The prevalence of
syphilis seroreactivity in the general population is
believed to be low (0.71%).2 Our study aims to determine whether it is cost-effective to screen for syphilis in
cases of suspected gonorrhea and chlamydia.

The emergency department charts from January 2004
to August 2006 were reviewed for the following test
results: gonorrhea DNA probe, chlamydia DNA probe,
and syphilis IgG (immunoglobulin G)/RPR (rapid
plasma reagin).
1

New York Medical College, Metropolitan Hospital Center, New
York, NY, USA
Corresponding Author:
Kumara V. Nibhanipudi, Professor of Clinical Emerg. Medicine,
New York Medical College, Metropolitan Hospital Center, 1901,
1st Avenue, New York, NY 10029, USA.
Email: kumarnibh@yahoo.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits noncommercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified
on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

2

Global Pediatric Health

Table 1. Data Summary.
Total # Charts
Reviewed
196

RPR
Positive

RPR
Negative

Chlamydia Positive,
Alone Probes

Gonococci Positive,
Alone Probes

Combined GC and
Chlamydia Positive Probes

0

78

67

6

5

Results
A total of 196 patients were screened for gonorrhea,
chlamydia, and syphilis during the above-mentioned
period. Seventy-eight patients tested positive for gonorrhea and/or chlamydia. All these 78 patients tested negative for syphilis. The overall prevalence of combined
gonorrhea and chlamydia was 39.8% (78/196). Among
positive testings, the prevalence of chlamydia alone was
67/78 (85.9.%), and that of gonorrhea alone was 6/78
(7.69%). The combined prevalence of both gonorrhea
and chlamydia in patients was 5/78 (6.4%). The total
number of patients screened for gonorrhea, chlamydia,
and syphilis during the above-mentioned period was
196. All 196 patients tested negative for syphilis; Of 196
tested, 78 patients tested positive for gonorrhea and
chlamydia either combined or alone was 39.8%(78/196).
The combined prevalence of gonorrhea and chlamydia
was 3% (6/196), whereas that of chlamydia alone was
67/196 (34%; and gonorrhea alone was 6/196 (3.06%)
see Table 1 and Figure 1).

Statistics
We used online SILICO 2 × 4 Fisher exact test. By comparing positive and negative results of serology RPR,
GC, and chlamydia trap, the resultant 2-tailed P value is
<.0001, which is statistically significant.

Discussion
According to the World Health Organization, there are
12 million new cases of syphilis annually worldwide.
Most patients who have syphilis are asymptomatic, and
serological testing is required to make a diagnosis. Per
the Centers for Disease Control and Prevention (CDC),
US syphilis rates declined to an all-time low in 2000
(2.2 cases per 100 000 cases). Marion County, Indiana,
had the highest incidence with 37.1 cases per 100 000
population. The incidence of gonorrhea is declining
(113.5 cases per 100 000), whereas the incidence of
chlamydia (319.6 per 100 000) is rising per the CDC
November 2005 data.
The CDC reports increased incidence of syphilis in
black men (7.7 cases per 100 000 in 2004), and the incidence of syphilis among women remained the same at
0.8 cases per 100 000. The CDC also reported that the

200
180
160
140

Total

120

#of

100

cases

80
60
40
20
0

Total
No Syphilis
Screened

GC

CH

GC/CH

Figure 1. Data summary.

incidence of chlamydia cases was 3.3 times higher
among women than men in 2004.
The US Preventive Services Task Force (USPSTF)
concluded the following: No direct evidence exists that
screening for syphilis infection leads to improved health
outcomes in persons at increased risk. Routine screening
of asymptomatic persons is not recommended in patients
not at increased risk for syphilis infection. There is no
evidence supporting routine screening for syphilis in
patients diagnosed with other sexually transmitted diseases. The potential harm of screening (cost, false-positive tests, and stigma) in a low incidence population
outweighs the benefits.3
The USPSTF does not recommend routine screening
for syphilis in asymptomatic low-risk individuals. But
according to the USPSTF, persons diagnosed with chlamydia, gonorrhea, or genital herpes are at higher risk for
acquiring syphilis and they recommend screening for
syphilis in these individuals.
Per authors Swygard et al, screening for syphilis is
recommended for commercial sex workers, persons in
correctional facilities, persons diagnosed with another
STD, men who have sex with men who engage in highrisk behavior, and all pregnant women at the first prenatal visit.4
According to Risser et al, the syphilis rate in southern states is 4.3 cases per 100 000 persons. Rates per
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100 000 persons for syphilis in 2006 were 4.9 among
African American; 0.8 among Hispanic women, and 0.3
among white women; these rates were in 2020, respectively, 24.5, 4.0, and 1.5, that is, 13 time greater than the
Healthy People.5
According to the CDC, during 1998 to 2002, the
number of syphilis cases among 16 men who have sex
with men (MSM) in San Francisco increased from 8 to
512 per 100 000 MSM.6
Syphilis testing is not cost-effective in detecting
syphilis in HIV-negative blood donors. Each year 18
million dollars is spent on serological tests for syphilis,
with another extra cost of 3.9 20 million dollars spent on
discarding specimens.7
Wangnapi et al reported, in pregnant women in
Papua, New Guinea, that the prevalence of Chlamydia
trachomatis was 11.1%, Neisseria gonorrhoeae 9.7%,
and Trichomonas vaginalis 21.3%. Risk factors included
having a partner at perceived risk of infection, maternal
extramarital intercourse, early sexual debut, lack of formal education, urban residence, smoking, and women
not using condoms.8
Kenyon et al found out that in most populations,
antenatal syphilis prevalence (ASP) dropped to under
1% before 1960. In Zimbabwe and black South Africans,
ASP was high in the pre-penicillin period, dropped in
the post-penicillin period, but then plateaued at around
6% until the end of the 20th century.9
Ballah and colleagues indicated that strengthening
current surveillance systems for syphilis is important to
track and monitor disease burden. Usage of routinely
collected laboratory information to generate surveillance was proposed in South Africa; annually for the
period from 2003 to 2012 there was an approximate
14% reduction of syphilis seroprevalence.10
Smith and Angarone reported that STIs remain a significant burden on public health in the United States.
Primary prevention counseling with early diagnosis and
treatment remain the best methods to decrease the incidence of STIs. Smith and Angarone conclude that
through significant public heath interventions, the incidence of gonorrhea, chlamydia, and trichomonas is
decreasing, but surprisingly the incidence of primary
and secondary syphilis is increasing.11
Nuñez-Forero et al tried to determine the diagnostic
accuracy of tests developed for use at the point of care
for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and syphilis in women having symptoms
of lower urinary tract infection. According to the authors,
rapid tests studies are not useful for screening for NG at
the point of care. But, in pregnant women, rapid tests
has been recommended for chlamydia and syphilis. In
the case of CT, a recommendation about their use in

routine care should be supported by a cost-effectiveness
analysis. In screening populations, such as people at
high risk of STIs or pregnant women, the RTs for syphilis were recommended.12
The National Profile STD Surveillance summarizes
that the national rate of syphilis cases reached an historic low in 2000 and 2001, but has increased almost
every year since then. This increase was largely attributable to an increase among men, and among MSM.
However, during 2013 to 2014, rates increased among
both men and women in every region of the country.
Rates of reported congenital syphilis cases also increased
in every region of the country during 2013 to 2014.
MSM continued to account for most P&S (primary
and secondary) syphilis cases in 2014. Nationally, the
highest rates of P&S syphilis in 2014 were observed
among men aged 20 to 24 years and 25 to 29 years,
among men in the West and in the South, and among
black men.13
The CDC in their 2014 Surveillance report has
reported that cases of chlamydia, gonorrhea, and syphilis have increased for the first time since 2006. In 2014,
there were 350 062 reported cases of gonorrhea (a rate
of 110.7 per 100 000) and 19 999 reported cases of P&S
syphilis (for a rate of 6.3 per 100 000). Sexually transmitted diseases continue to affect young people—particularly women—most severely, but increasing rates
among men contributed to the overall increases in 2014
across all 3 diseases. To reduce Sexually transmitted
diseases, Americans must take steps to protect themselves. For sexually active individuals, testing and
treatment according to CDC’s recommendations, using
condoms consistently and correctly, and limiting the
number of sex partners are all effective strategies for
reducing the risk of infection and consequences to
health.14
Our study concurs with recommendations in other
studies. Even though syphilis is on the rise in certain
populations and USPSTF recommends serological tests
for syphilis, it is evident from our study that the yield is
poor or negligible and hence it is not a cost-effective
screening procedure.

Limitations
The limitation of our study is the small sample size.

Conclusions
Per our study, the yield of syphilis testing was negligible. It was not cost-effective to screen for syphilis ($4
per test for RPR) in all cases of suspected gonorrhea and
chlamydia.
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